Rockymore v. Eurofins Donor & Product Testing, Inc.

District Court, N.D. California·Decided July 11, 2022·No. 3:22-cv-00176·Unknown

Opinion

1 2 3 6 7 MONETTE ROCKYMORE, Case No. 3:22-cv-00176-WHO

8 Plaintiff, ORDER ON MOTION TO DISMISS v. 9 Re: Dkt. No. 33 TESTING, INC., et al., 11 Defendants.

12 13 Plaintiff Monette Rockymore alleges, as relevant to this motion, that her former employer, 14 defendant Eurofins Donor & Product Testing, Inc. (“Eurofins”), is liable for hostile work 15 environment harassment (and failure to prevent it), intentional infliction of emotional distress 16 (“IIED”), failure to prevent retaliation for opposing discrimination, and breach of contract for 17 terminating her without good cause. Eurofins moves to dismiss those claims, which I previously 18 dismissed with leave to amend. The motion is DENIED on the claims for harassment, IIED, and 19 failure to prevent retaliation, which are now plausibly pleaded. It is GRANTED without leave to 20 amend on the breach of contract claims; even accepting the well-pleaded allegations in the 21 complaint as true, no express or implied good-cause termination contract was formed.1 23 Rockymore is a woman and identifies herself as “Pacific Islander/Asian.” First Amended 24 Complaint (“FAC”) [Dkt. No. 32] ¶ 10.a. Some of the defendants are a related group of entities. 25 Eurofins is a corporation with its headquarters in Pennsylvania and, as relevant here, an office in 26 San Ramon, California. See Order on Motions to Remand and Dismiss (“Prior Order”) [Dkt. No. 27 1 30] 6; FAC ¶ 2. Several other associated entities are named as defendants in the complaint, which 2 will be collectively referred to here as the Divisional Defendants.2 Their status is one subject of 3 this motion and is discussed below; in short, they are divisions of Eurofins, not separate entities. 4 Rockymore has also sued individuals Brendan O’Neale, Sara Dionne, and Rohini Ratnam. 5 Eurofins hired Rockymore in July 2018 as a laboratory manager. FAC ¶ 8. She alleges 6 that she has “cervical lymphadenopathy,” which she calls a “viral infection that causes severe liver 7 and kidney inflammation.” Id. ¶ 10.b. This condition, she says, “required her to have frequent 8 doctor visits” that she informed the defendants about. Id. It also required her to “take protected 9 medical leaves.” Id. 10 In November 2019, Dionne hired O’Neale as a regional manager to whom Rockymore 11 reported. Id. ¶ 12.a. Rockymore alleges that she “immediately felt discriminated [against] and 12 harassed” by O’Neale. Id. She claims that he “disfavored” her and other women and 13 “disregarded” her advice. Id. At one point, he approached Rockymore and her team and 14 “sarcastic[ally]” said, “[i]s there anything you guys want to brag about?” Id. Rockymore reported 15 this to Dionne. Id. In February 2020, on a work trip, Dionne and another employee (who is not a 16 defendant) told Rockymore that “she was being written up for” coming “into the office in the 17 middle of the night to complete an urgent request from a client in a timely manner.” Id. ¶ 12.b. 18 Rockymore alleges that doing so was “normal practice,” that another employee had done the same 19 thing without being written up, and that she was “shocked.” Id. 20 In March 2020, O’Neale dismissed an employee that Rockymore supervised without her 21 knowledge and said it was part of a “reduction in workforce.” Id. ¶ 12.c. Rockymore complained 22 to human resources but never heard back. Id. She claims that “the majority of male and non- 23 Asian” managers at other labs “had access to subordinates to complete” their work while she “was 24 the only [one] affected by the ‘reduction in workforce.’” Id. She also complained to human 25 resources that she received less support than male and non-Asian employees, but there was no 26

27 2 The Divisional Defendants are Eurofins Denver Corporate, Eurofins Pre-Transplant Testing, 1 result. Id. Rockymore’s “workload became extremely high” and she could not fill three vacancies 2 in her lab. Id. She asked O’Neale and human resources to hire for these vacancies, but she was 3 not granted permission. Id. 4 In April 2020, Rockymore became “severely sick” with “COVID-19 symptoms.” Id. ¶ 5 12.d. She took medical leave and, after returning, claims that her “work environment worsened.” 6 Id. She alleges that O’Neale gave her assignments with “unrealistic timelines, provided her with 7 no support, and heavily micromanaged her,” causing “stress and anxiety.” Id. She “repeatedly” 8 informed O’Neale that she had inadequate support, but he denied her any more. Id. She also 9 repeatedly complained over three months to O’Neale because he failed to conduct a performance 10 review for her, despite doing so for “all other managers.” Id. ¶ 12.e. That review was finalized in 11 August 2020; Rockymore alleges that O’Neale gave her an “unde[]served negative performance 12 review despite her continued perform [sic] her job duties in an exemplary manner as exemplified 13 by the successful support of projects as noted in her performance reviews.” Id. 14 Rockymore also alleges that an unspecified “defendant” “would make oral and written 15 assurances of continued employment, and job security and including [sic] that Rockymore 16 continued to perform her job duties in an exemplary manner and that defendants would ‘continue 17 to work with Rockymore on stabilizing the San Ramon Lab Operations.’” Id. ¶ 12.f. (alteration 18 omitted). She characterizes this as creating a for-cause termination protection, an issue discussed 19 below. Id. 20 On September 10, 2020, Rockymore developed a high fever and was told by her doctor not 21 to go into work due to concerns about COVID-19. Id. ¶ 12.g. Rockymore then developed 22 “inflammation to her liver and kidney.” Id. She was placed on medical leave through September 23 30, 2020. Id. During this leave, O’Neale and Dionne “continued to email her requesting tasks to 24 be completed for work related [sic] projects.” Id. Rockymore responded by asking Dionne to 25 “request help from others.” Id. On September 17, she complained to Dionne about “being 26 removed from communications regarding a business project” with which she had been heavily 27 involved and received no response. Id. 1 “performance issues.” Id. She was “shock[ed]” and “felt sick to her stomach.” Id. She alleges 2 that she had “just launched a successful project” and had never been “informed of any 3 performance issues.” Id. 4 Rockymore filed this suit in California state court on December 6, 2021, and it was 5 removed to this court in January 2022. Dkt. No. 1. In April 2022, I granted in part and denied in 6 part a motion to dismiss and denied a motion to remand. See generally Prior Order. I found 7 Rockymore’s claims for race and gender discrimination, retaliation, failure to provide a reasonable 8 accommodation, and negligent supervision plausibly pleaded. Id. 1. But I granted the motion 9 with leave to amend on claims for disability discrimination, hostile work environment, breach of 10 contract, and IIED. Id. Rockymore filed her FAC in May 2022 and Eurofins again moves to 11 dismiss. 13 Under Federal Rule of Civil Procedure 12(b)(6), a district court must dismiss a complaint 14 if it fails to state a claim upon which relief can be granted. To survive a Rule 12(b)(6) motion to 15 dismiss, the plaintiff must allege “enough facts to state a claim to relief that is plausible on its 16 face.” See Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim is facially plausible 17 when the plaintiff pleads facts that “allow the court to draw the reasonable inference that the 18 defendant is liable for the misconduct alleged.” See Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) 19 (citation omitted).

Free access — add to your briefcase to read the full text and ask questions with AI

Rockymore v. Eurofins Donor & Product Testing, Inc., (N.D. Cal. 2022).

Rockymore v. Eurofins Donor & Product Testing, Inc. (Rockymore v. Eurofins Donor & Product Testing, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Retired Employees Ass'n of Orange County, Inc. v. County of Orange
266 P.3d 287 (California Supreme Court, 2011)
In Re Gilead Sciences Securities Litigation
536 F.3d 1049 (Ninth Circuit, 2008)
Aguilar v. Avis Rent a Car System, Inc.
980 P.2d 846 (California Supreme Court, 1999)
Janken v. GM Hughes Electronics
46 Cal. App. 4th 55 (California Court of Appeal, 1996)
Stillwell v. the Salvation Army
167 Cal. App. 4th 360 (California Court of Appeal, 2008)
Taylor v. City of Los Angeles Department of Water & Power
51 Cal. Rptr. 3d 206 (California Court of Appeal, 2006)
Jones v. Lodge at Torrey Pines Partnership
177 P.3d 232 (California Supreme Court, 2008)
Yanowitz v. L'OREAL USA, INC.
116 P.3d 1123 (California Supreme Court, 2005)
Guz v. Bechtel National, Inc.
8 P.3d 1089 (California Supreme Court, 2000)
Hughes v. Pair
209 P.3d 963 (California Supreme Court, 2009)
Roby v. McKesson Corp.
219 P.3d 749 (California Supreme Court, 2009)
Mariani v. Dougherty
46 Cal. 26 (California Supreme Court, 1873)
Brennan v. Townsend & O'Leary Enterprises, Inc.
199 Cal. App. 4th 1336 (California Court of Appeal, 2011)
Lopez v. Smith
203 F.3d 1122 (Ninth Circuit, 2000)